• LAST PRICE
    3.6900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.5700/ 1
  • Ask / Lots
    3.7900/ 1
  • Open / Previous Close
    3.6800 / 3.6900
  • Day Range
    Low 3.6700
    High 3.7450
  • 52 Week Range
    Low 2.7650
    High 5.1900
  • Volume
    174,652
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.7
TimeVolumeAVIR
09:32 ET17123.68
09:36 ET5003.675
09:38 ET39263.695
09:39 ET1003.69
09:41 ET29093.69
09:48 ET1003.705
09:50 ET1003.705
09:52 ET2003.7095
09:54 ET1003.71
09:56 ET6253.705
09:57 ET1003.71
09:59 ET3003.71
10:01 ET10333.7
10:03 ET72313.715
10:06 ET1003.72
10:10 ET3003.74
10:12 ET12673.745
10:14 ET12003.735
10:15 ET1003.74
10:17 ET1003.74
10:21 ET4893.73
10:24 ET1003.73
10:26 ET15003.73
10:28 ET4003.735
10:30 ET4803.74
10:33 ET13443.74
10:35 ET1003.735
10:37 ET1003.74
10:39 ET3673.74
10:42 ET11003.72
10:44 ET5343.72
10:46 ET26043.72
10:50 ET1003.7125
10:53 ET1003.715
10:55 ET3003.7195
11:00 ET6513.725
11:02 ET21383.725
11:04 ET3003.735
11:11 ET1003.735
11:13 ET7443.735
11:15 ET1003.735
11:18 ET13003.725
11:24 ET3003.725
11:26 ET2003.725
11:31 ET10023.725
11:33 ET29263.71
11:38 ET7003.695
11:42 ET2003.695
11:45 ET6003.7
11:51 ET1003.695
11:54 ET2163.695
11:56 ET2003.695
11:58 ET1003.69
12:00 ET1003.69
12:02 ET1003.69
12:03 ET5003.7
12:05 ET10003.705
12:12 ET1003.705
12:16 ET4003.71
12:20 ET1003.7
12:25 ET1653.7001
12:27 ET4003.71
12:32 ET1003.705
12:34 ET1003.705
12:38 ET2003.7
12:41 ET1003.705
12:48 ET1003.705
12:52 ET2003.705
12:57 ET1003.7
01:03 ET1303.705
01:06 ET2003.71
01:08 ET1003.705
01:12 ET2003.705
01:14 ET2003.705
01:17 ET4003.71
01:24 ET15473.705
01:35 ET46043.705
01:42 ET2003.71
01:44 ET1003.7073
01:48 ET2003.71
01:50 ET1253.7086
01:51 ET5003.71
01:53 ET2663.72
01:55 ET2003.725
01:57 ET1003.725
02:00 ET1003.725
02:02 ET2003.725
02:04 ET12003.72
02:08 ET2003.7195
02:11 ET1003.715
02:18 ET2013.715
02:20 ET2103.715
02:22 ET4003.71
02:24 ET2003.715
02:26 ET2003.715
02:27 ET1003.715
02:29 ET28433.6995
02:31 ET1003.69
02:33 ET6043.695
02:38 ET1003.695
02:42 ET1003.695
02:44 ET3043.695
02:47 ET1003.695
02:49 ET1003.695
02:51 ET1003.695
02:56 ET1003.695
02:58 ET1203.6989
03:00 ET1003.69
03:02 ET2003.69
03:05 ET3003.69
03:07 ET1003.695
03:09 ET1003.695
03:14 ET1003.69
03:16 ET4243.695
03:20 ET29643.695
03:21 ET3013.7
03:25 ET2003.695
03:27 ET1003.695
03:30 ET2003.695
03:32 ET5323.695
03:34 ET14103.695
03:36 ET1003.68
03:38 ET3003.69
03:41 ET1003.685
03:43 ET3843.685
03:48 ET2003.68
03:50 ET3003.685
03:52 ET1003.685
03:54 ET6043.69
03:56 ET8603.685
03:57 ET3213.69
03:59 ET7053.69
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVIR
Atea Pharmaceuticals Inc
311.4M
-2.3x
---
United StatesATAI
ATAI Life Sciences NV
310.5M
-6.5x
---
United StatesTERN
Terns Pharmaceuticals Inc
307.1M
-3.7x
---
United StatesLYRA
Lyra Therapeutics Inc
312.5M
-3.9x
---
United StatesGUTS
Fractyl Health Inc
301.2M
-3.4x
---
United StatesNAUT
Nautilus Biotechnology Inc
300.2M
-4.6x
---
As of 2024-04-26

Company Information

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Contact Information

Headquarters
225 Franklin Street, Suite 2100BOSTON, MA, United States 02110
Phone
857-204-8109
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Jean-Pierre Sommadossi
Chief Financial Officer, Executive Vice President - Legal , Secretary
Andrea Corcoran
Executive Vice President, Chief Accounting Officer
Wayne Foster
Chief Development Officer
Janet Hammond
Chief Medical Officer
Maria Horga

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$311.4M
Revenue (TTM)
$0.00
Shares Outstanding
84.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.19
EPS
$-1.63
Book Value
$6.65
P/E Ratio
-2.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.